Global RDC Drugs Market 2026 by Company, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global RDC Drugs market size was valued at US$ 11040 million in 2025 and is forecast to a readjusted size of US$ 20030 million by 2032 with a CAGR of 9.0% during review period.
RDC (Radiopharmaceutical Drug Conjugate) drugs represent a class of precision therapeutic or diagnostic agents formed by linking molecules capable of targeted recognition with radionuclides via chelators or chemical linkers. Their core mechanism relies on 'targeted delivery combined with localized radioactive killing or imaging' to achieve highly selective treatment or visualization of tumors or specific lesions?such as in PSMA-targeted therapy for prostate cancer or the management of neuroendocrine tumors. This field is currently a key area of ??development in nuclear medicine and precision oncology.
In terms of the industry value chain, the upstream sector encompasses the production of medical radioisotopes, the supply of stable isotopes, the provision of chemical materials (chelators and linkers), and the R&D of targeting ligands. The midstream sector consists of companies dedicated to R&D and formulation, handling radionuclide labeling processes, quality control, GMP-compliant radiopharmaceutical preparation, and the logistics of cold-chain or decay-in-storage management. The downstream sector comprises hospital nuclear medicine departments, oncology centers, and PET/SPECT diagnostic and radiotherapy facilities, where patient administration, imaging, and therapeutic applications take place; this sector operates within a robust regulatory framework that imposes strict industry constraints.
Regarding future prospects, the RDC drug sector is in the early stages of a global boom, driven by the rising demand for precision oncology, the maturation of radionuclide supply chains, and the widespread adoption of the 'theranostics' (combined diagnosis and therapy) model. Future growth is expected to stem from expanded indications for prostate cancer, neuroendocrine tumors, breast cancer, and other solid tumors, while alpha-radionuclide therapies promise to drive a new wave of technological advancement. Characterized by high barriers to entry, rapid growth, and high unit prices, the industry is expected to continue attracting major pharmaceutical companies and nuclear technology firms.
This report is a detailed and comprehensive analysis for global RDC Drugs market. Both quantitative and qualitative analyses are presented by company, by region & country, by Target Ligand Types and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global RDC Drugs market size and forecasts, in consumption value ($ Million), 2021-2032
Global RDC Drugs market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global RDC Drugs market size and forecasts, by Target Ligand Types and by Application, in consumption value ($ Million), 2021-2032
Global RDC Drugs market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
RDC Drugs market is split by Target Ligand Types and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Target Ligand Types and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Target Ligand Types
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe RDC Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of RDC Drugs, with revenue, gross margin, and global market share of RDC Drugs from 2021 to 2026.
Chapter 3, the RDC Drugs competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Target Ligand Types and by Application, with consumption value and growth rate by Target Ligand Types, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and RDC Drugs market forecast, by regions, by Target Ligand Types and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of RDC Drugs.
Chapter 13, to describe RDC Drugs research findings and conclusion.
RDC (Radiopharmaceutical Drug Conjugate) drugs represent a class of precision therapeutic or diagnostic agents formed by linking molecules capable of targeted recognition with radionuclides via chelators or chemical linkers. Their core mechanism relies on 'targeted delivery combined with localized radioactive killing or imaging' to achieve highly selective treatment or visualization of tumors or specific lesions?such as in PSMA-targeted therapy for prostate cancer or the management of neuroendocrine tumors. This field is currently a key area of ??development in nuclear medicine and precision oncology.
In terms of the industry value chain, the upstream sector encompasses the production of medical radioisotopes, the supply of stable isotopes, the provision of chemical materials (chelators and linkers), and the R&D of targeting ligands. The midstream sector consists of companies dedicated to R&D and formulation, handling radionuclide labeling processes, quality control, GMP-compliant radiopharmaceutical preparation, and the logistics of cold-chain or decay-in-storage management. The downstream sector comprises hospital nuclear medicine departments, oncology centers, and PET/SPECT diagnostic and radiotherapy facilities, where patient administration, imaging, and therapeutic applications take place; this sector operates within a robust regulatory framework that imposes strict industry constraints.
Regarding future prospects, the RDC drug sector is in the early stages of a global boom, driven by the rising demand for precision oncology, the maturation of radionuclide supply chains, and the widespread adoption of the 'theranostics' (combined diagnosis and therapy) model. Future growth is expected to stem from expanded indications for prostate cancer, neuroendocrine tumors, breast cancer, and other solid tumors, while alpha-radionuclide therapies promise to drive a new wave of technological advancement. Characterized by high barriers to entry, rapid growth, and high unit prices, the industry is expected to continue attracting major pharmaceutical companies and nuclear technology firms.
This report is a detailed and comprehensive analysis for global RDC Drugs market. Both quantitative and qualitative analyses are presented by company, by region & country, by Target Ligand Types and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global RDC Drugs market size and forecasts, in consumption value ($ Million), 2021-2032
Global RDC Drugs market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global RDC Drugs market size and forecasts, by Target Ligand Types and by Application, in consumption value ($ Million), 2021-2032
Global RDC Drugs market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
- To determine the size of the total market opportunity of global and key countries
- To assess the growth potential for RDC Drugs
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
RDC Drugs market is split by Target Ligand Types and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Target Ligand Types and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Target Ligand Types
- Antibody-Drug Conjugates (ARC)
- Peptide-Drug Conjugates (PRC)
- Small Molecule-Drug Conjugates (SMRC)
- Diagnostic RDCs
- Therapeutic RDCs
- ?-Nuclear Therapy
- ?-Nuclear Therapy
- Prostate Cancer
- Neuroendocrine Tumors
- Liver Cancer
- Kidney Cancer
- Bone Metastases
- Others
- Novartis
- Bayer
- AstraZeneca
- Eli Lilly
- Bristol-Myers Squibb
- Johnson & Johnson
- Grand Pharmaceutical Group
- China Isotope & Radiation Corporation
- Dongcheng Pharmaceutical
- Hengrui Medicine
- Xiantong Pharmaceutical
- Bivision
- SmartNuclide
- Full-Life Technologies
- Hexin (Suzhou) Pharmaceutical Technology Co., Ltd.
- Nuoyu Pharmaceutical
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe RDC Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of RDC Drugs, with revenue, gross margin, and global market share of RDC Drugs from 2021 to 2026.
Chapter 3, the RDC Drugs competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Target Ligand Types and by Application, with consumption value and growth rate by Target Ligand Types, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and RDC Drugs market forecast, by regions, by Target Ligand Types and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of RDC Drugs.
Chapter 13, to describe RDC Drugs research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of RDC Drugs by Target Ligand Types
1.3.1 Overview: Global RDC Drugs Market Size by Target Ligand Types: 2021 Versus 2025 Versus 2032
1.3.2 Global RDC Drugs Consumption Value Market Share by Target Ligand Types in 2025
1.3.3 Antibody-Drug Conjugates (ARC)
1.3.4 Peptide-Drug Conjugates (PRC)
1.3.5 Small Molecule-Drug Conjugates (SMRC)
1.4 Classification of RDC Drugs by Medical Uses
1.4.1 Overview: Global RDC Drugs Market Size by Medical Uses: 2021 Versus 2025 Versus 2032
1.4.2 Global RDC Drugs Consumption Value Market Share by Medical Uses in 2025
1.4.3 Diagnostic RDCs
1.4.4 Therapeutic RDCs
1.5 Classification of RDC Drugs by Therapeutic Radionuclide Properties
1.5.1 Overview: Global RDC Drugs Market Size by Therapeutic Radionuclide Properties: 2021 Versus 2025 Versus 2032
1.5.2 Global RDC Drugs Consumption Value Market Share by Therapeutic Radionuclide Properties in 2025
1.5.3 ?-Nuclear Therapy
1.5.4 ?-Nuclear Therapy
1.6 Global RDC Drugs Market by Application
1.6.1 Overview: Global RDC Drugs Market Size by Application: 2021 Versus 2025 Versus 2032
1.6.2 Prostate Cancer
1.6.3 Neuroendocrine Tumors
1.6.4 Liver Cancer
1.6.5 Kidney Cancer
1.6.6 Bone Metastases
1.6.7 Others
1.7 Global RDC Drugs Market Size & Forecast
1.8 Global RDC Drugs Market Size and Forecast by Region
1.8.1 Global RDC Drugs Market Size by Region: 2021 VS 2025 VS 2032
1.8.2 Global RDC Drugs Market Size by Region, (2021-2032)
1.8.3 North America RDC Drugs Market Size and Prospect (2021-2032)
1.8.4 Europe RDC Drugs Market Size and Prospect (2021-2032)
1.8.5 Asia-Pacific RDC Drugs Market Size and Prospect (2021-2032)
1.8.6 South America RDC Drugs Market Size and Prospect (2021-2032)
1.8.7 Middle East & Africa RDC Drugs Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Novartis
2.1.1 Novartis Details
2.1.2 Novartis Major Business
2.1.3 Novartis RDC Drugs Product and Solutions
2.1.4 Novartis RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Novartis Recent Developments and Future Plans
2.2 Bayer
2.2.1 Bayer Details
2.2.2 Bayer Major Business
2.2.3 Bayer RDC Drugs Product and Solutions
2.2.4 Bayer RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Bayer Recent Developments and Future Plans
2.3 AstraZeneca
2.3.1 AstraZeneca Details
2.3.2 AstraZeneca Major Business
2.3.3 AstraZeneca RDC Drugs Product and Solutions
2.3.4 AstraZeneca RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 AstraZeneca Recent Developments and Future Plans
2.4 Eli Lilly
2.4.1 Eli Lilly Details
2.4.2 Eli Lilly Major Business
2.4.3 Eli Lilly RDC Drugs Product and Solutions
2.4.4 Eli Lilly RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Eli Lilly Recent Developments and Future Plans
2.5 Bristol-Myers Squibb
2.5.1 Bristol-Myers Squibb Details
2.5.2 Bristol-Myers Squibb Major Business
2.5.3 Bristol-Myers Squibb RDC Drugs Product and Solutions
2.5.4 Bristol-Myers Squibb RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.6 Johnson & Johnson
2.6.1 Johnson & Johnson Details
2.6.2 Johnson & Johnson Major Business
2.6.3 Johnson & Johnson RDC Drugs Product and Solutions
2.6.4 Johnson & Johnson RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Johnson & Johnson Recent Developments and Future Plans
2.7 Grand Pharmaceutical Group
2.7.1 Grand Pharmaceutical Group Details
2.7.2 Grand Pharmaceutical Group Major Business
2.7.3 Grand Pharmaceutical Group RDC Drugs Product and Solutions
2.7.4 Grand Pharmaceutical Group RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Grand Pharmaceutical Group Recent Developments and Future Plans
2.8 China Isotope & Radiation Corporation
2.8.1 China Isotope & Radiation Corporation Details
2.8.2 China Isotope & Radiation Corporation Major Business
2.8.3 China Isotope & Radiation Corporation RDC Drugs Product and Solutions
2.8.4 China Isotope & Radiation Corporation RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 China Isotope & Radiation Corporation Recent Developments and Future Plans
2.9 Dongcheng Pharmaceutical
2.9.1 Dongcheng Pharmaceutical Details
2.9.2 Dongcheng Pharmaceutical Major Business
2.9.3 Dongcheng Pharmaceutical RDC Drugs Product and Solutions
2.9.4 Dongcheng Pharmaceutical RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Dongcheng Pharmaceutical Recent Developments and Future Plans
2.10 Hengrui Medicine
2.10.1 Hengrui Medicine Details
2.10.2 Hengrui Medicine Major Business
2.10.3 Hengrui Medicine RDC Drugs Product and Solutions
2.10.4 Hengrui Medicine RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Hengrui Medicine Recent Developments and Future Plans
2.11 Xiantong Pharmaceutical
2.11.1 Xiantong Pharmaceutical Details
2.11.2 Xiantong Pharmaceutical Major Business
2.11.3 Xiantong Pharmaceutical RDC Drugs Product and Solutions
2.11.4 Xiantong Pharmaceutical RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Xiantong Pharmaceutical Recent Developments and Future Plans
2.12 Bivision
2.12.1 Bivision Details
2.12.2 Bivision Major Business
2.12.3 Bivision RDC Drugs Product and Solutions
2.12.4 Bivision RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 Bivision Recent Developments and Future Plans
2.13 SmartNuclide
2.13.1 SmartNuclide Details
2.13.2 SmartNuclide Major Business
2.13.3 SmartNuclide RDC Drugs Product and Solutions
2.13.4 SmartNuclide RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 SmartNuclide Recent Developments and Future Plans
2.14 Full-Life Technologies
2.14.1 Full-Life Technologies Details
2.14.2 Full-Life Technologies Major Business
2.14.3 Full-Life Technologies RDC Drugs Product and Solutions
2.14.4 Full-Life Technologies RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 Full-Life Technologies Recent Developments and Future Plans
2.15 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd.
2.15.1 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Details
2.15.2 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Major Business
2.15.3 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. RDC Drugs Product and Solutions
2.15.4 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.15.5 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Recent Developments and Future Plans
2.16 Nuoyu Pharmaceutical
2.16.1 Nuoyu Pharmaceutical Details
2.16.2 Nuoyu Pharmaceutical Major Business
2.16.3 Nuoyu Pharmaceutical RDC Drugs Product and Solutions
2.16.4 Nuoyu Pharmaceutical RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.16.5 Nuoyu Pharmaceutical Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global RDC Drugs Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of RDC Drugs by Company Revenue
3.2.2 Top 3 RDC Drugs Players Market Share in 2025
3.2.3 Top 6 RDC Drugs Players Market Share in 2025
3.3 RDC Drugs Market: Overall Company Footprint Analysis
3.3.1 RDC Drugs Market: Region Footprint
3.3.2 RDC Drugs Market: Company Product Type Footprint
3.3.3 RDC Drugs Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TARGET LIGAND TYPES
4.1 Global RDC Drugs Consumption Value and Market Share by Target Ligand Types (2021-2026)
4.2 Global RDC Drugs Market Forecast by Target Ligand Types (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global RDC Drugs Consumption Value Market Share by Application (2021-2026)
5.2 Global RDC Drugs Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America RDC Drugs Consumption Value by Target Ligand Types (2021-2032)
6.2 North America RDC Drugs Market Size by Application (2021-2032)
6.3 North America RDC Drugs Market Size by Country
6.3.1 North America RDC Drugs Consumption Value by Country (2021-2032)
6.3.2 United States RDC Drugs Market Size and Forecast (2021-2032)
6.3.3 Canada RDC Drugs Market Size and Forecast (2021-2032)
6.3.4 Mexico RDC Drugs Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe RDC Drugs Consumption Value by Target Ligand Types (2021-2032)
7.2 Europe RDC Drugs Consumption Value by Application (2021-2032)
7.3 Europe RDC Drugs Market Size by Country
7.3.1 Europe RDC Drugs Consumption Value by Country (2021-2032)
7.3.2 Germany RDC Drugs Market Size and Forecast (2021-2032)
7.3.3 France RDC Drugs Market Size and Forecast (2021-2032)
7.3.4 United Kingdom RDC Drugs Market Size and Forecast (2021-2032)
7.3.5 Russia RDC Drugs Market Size and Forecast (2021-2032)
7.3.6 Italy RDC Drugs Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific RDC Drugs Consumption Value by Target Ligand Types (2021-2032)
8.2 Asia-Pacific RDC Drugs Consumption Value by Application (2021-2032)
8.3 Asia-Pacific RDC Drugs Market Size by Region
8.3.1 Asia-Pacific RDC Drugs Consumption Value by Region (2021-2032)
8.3.2 China RDC Drugs Market Size and Forecast (2021-2032)
8.3.3 Japan RDC Drugs Market Size and Forecast (2021-2032)
8.3.4 South Korea RDC Drugs Market Size and Forecast (2021-2032)
8.3.5 India RDC Drugs Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia RDC Drugs Market Size and Forecast (2021-2032)
8.3.7 Australia RDC Drugs Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America RDC Drugs Consumption Value by Target Ligand Types (2021-2032)
9.2 South America RDC Drugs Consumption Value by Application (2021-2032)
9.3 South America RDC Drugs Market Size by Country
9.3.1 South America RDC Drugs Consumption Value by Country (2021-2032)
9.3.2 Brazil RDC Drugs Market Size and Forecast (2021-2032)
9.3.3 Argentina RDC Drugs Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa RDC Drugs Consumption Value by Target Ligand Types (2021-2032)
10.2 Middle East & Africa RDC Drugs Consumption Value by Application (2021-2032)
10.3 Middle East & Africa RDC Drugs Market Size by Country
10.3.1 Middle East & Africa RDC Drugs Consumption Value by Country (2021-2032)
10.3.2 Turkey RDC Drugs Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia RDC Drugs Market Size and Forecast (2021-2032)
10.3.4 UAE RDC Drugs Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 RDC Drugs Market Drivers
11.2 RDC Drugs Market Restraints
11.3 RDC Drugs Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 RDC Drugs Industry Chain
12.2 RDC Drugs Upstream Analysis
12.3 RDC Drugs Midstream Analysis
12.4 RDC Drugs Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of RDC Drugs by Target Ligand Types
1.3.1 Overview: Global RDC Drugs Market Size by Target Ligand Types: 2021 Versus 2025 Versus 2032
1.3.2 Global RDC Drugs Consumption Value Market Share by Target Ligand Types in 2025
1.3.3 Antibody-Drug Conjugates (ARC)
1.3.4 Peptide-Drug Conjugates (PRC)
1.3.5 Small Molecule-Drug Conjugates (SMRC)
1.4 Classification of RDC Drugs by Medical Uses
1.4.1 Overview: Global RDC Drugs Market Size by Medical Uses: 2021 Versus 2025 Versus 2032
1.4.2 Global RDC Drugs Consumption Value Market Share by Medical Uses in 2025
1.4.3 Diagnostic RDCs
1.4.4 Therapeutic RDCs
1.5 Classification of RDC Drugs by Therapeutic Radionuclide Properties
1.5.1 Overview: Global RDC Drugs Market Size by Therapeutic Radionuclide Properties: 2021 Versus 2025 Versus 2032
1.5.2 Global RDC Drugs Consumption Value Market Share by Therapeutic Radionuclide Properties in 2025
1.5.3 ?-Nuclear Therapy
1.5.4 ?-Nuclear Therapy
1.6 Global RDC Drugs Market by Application
1.6.1 Overview: Global RDC Drugs Market Size by Application: 2021 Versus 2025 Versus 2032
1.6.2 Prostate Cancer
1.6.3 Neuroendocrine Tumors
1.6.4 Liver Cancer
1.6.5 Kidney Cancer
1.6.6 Bone Metastases
1.6.7 Others
1.7 Global RDC Drugs Market Size & Forecast
1.8 Global RDC Drugs Market Size and Forecast by Region
1.8.1 Global RDC Drugs Market Size by Region: 2021 VS 2025 VS 2032
1.8.2 Global RDC Drugs Market Size by Region, (2021-2032)
1.8.3 North America RDC Drugs Market Size and Prospect (2021-2032)
1.8.4 Europe RDC Drugs Market Size and Prospect (2021-2032)
1.8.5 Asia-Pacific RDC Drugs Market Size and Prospect (2021-2032)
1.8.6 South America RDC Drugs Market Size and Prospect (2021-2032)
1.8.7 Middle East & Africa RDC Drugs Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Novartis
2.1.1 Novartis Details
2.1.2 Novartis Major Business
2.1.3 Novartis RDC Drugs Product and Solutions
2.1.4 Novartis RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Novartis Recent Developments and Future Plans
2.2 Bayer
2.2.1 Bayer Details
2.2.2 Bayer Major Business
2.2.3 Bayer RDC Drugs Product and Solutions
2.2.4 Bayer RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Bayer Recent Developments and Future Plans
2.3 AstraZeneca
2.3.1 AstraZeneca Details
2.3.2 AstraZeneca Major Business
2.3.3 AstraZeneca RDC Drugs Product and Solutions
2.3.4 AstraZeneca RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 AstraZeneca Recent Developments and Future Plans
2.4 Eli Lilly
2.4.1 Eli Lilly Details
2.4.2 Eli Lilly Major Business
2.4.3 Eli Lilly RDC Drugs Product and Solutions
2.4.4 Eli Lilly RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Eli Lilly Recent Developments and Future Plans
2.5 Bristol-Myers Squibb
2.5.1 Bristol-Myers Squibb Details
2.5.2 Bristol-Myers Squibb Major Business
2.5.3 Bristol-Myers Squibb RDC Drugs Product and Solutions
2.5.4 Bristol-Myers Squibb RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.6 Johnson & Johnson
2.6.1 Johnson & Johnson Details
2.6.2 Johnson & Johnson Major Business
2.6.3 Johnson & Johnson RDC Drugs Product and Solutions
2.6.4 Johnson & Johnson RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Johnson & Johnson Recent Developments and Future Plans
2.7 Grand Pharmaceutical Group
2.7.1 Grand Pharmaceutical Group Details
2.7.2 Grand Pharmaceutical Group Major Business
2.7.3 Grand Pharmaceutical Group RDC Drugs Product and Solutions
2.7.4 Grand Pharmaceutical Group RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Grand Pharmaceutical Group Recent Developments and Future Plans
2.8 China Isotope & Radiation Corporation
2.8.1 China Isotope & Radiation Corporation Details
2.8.2 China Isotope & Radiation Corporation Major Business
2.8.3 China Isotope & Radiation Corporation RDC Drugs Product and Solutions
2.8.4 China Isotope & Radiation Corporation RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 China Isotope & Radiation Corporation Recent Developments and Future Plans
2.9 Dongcheng Pharmaceutical
2.9.1 Dongcheng Pharmaceutical Details
2.9.2 Dongcheng Pharmaceutical Major Business
2.9.3 Dongcheng Pharmaceutical RDC Drugs Product and Solutions
2.9.4 Dongcheng Pharmaceutical RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 Dongcheng Pharmaceutical Recent Developments and Future Plans
2.10 Hengrui Medicine
2.10.1 Hengrui Medicine Details
2.10.2 Hengrui Medicine Major Business
2.10.3 Hengrui Medicine RDC Drugs Product and Solutions
2.10.4 Hengrui Medicine RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Hengrui Medicine Recent Developments and Future Plans
2.11 Xiantong Pharmaceutical
2.11.1 Xiantong Pharmaceutical Details
2.11.2 Xiantong Pharmaceutical Major Business
2.11.3 Xiantong Pharmaceutical RDC Drugs Product and Solutions
2.11.4 Xiantong Pharmaceutical RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 Xiantong Pharmaceutical Recent Developments and Future Plans
2.12 Bivision
2.12.1 Bivision Details
2.12.2 Bivision Major Business
2.12.3 Bivision RDC Drugs Product and Solutions
2.12.4 Bivision RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 Bivision Recent Developments and Future Plans
2.13 SmartNuclide
2.13.1 SmartNuclide Details
2.13.2 SmartNuclide Major Business
2.13.3 SmartNuclide RDC Drugs Product and Solutions
2.13.4 SmartNuclide RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 SmartNuclide Recent Developments and Future Plans
2.14 Full-Life Technologies
2.14.1 Full-Life Technologies Details
2.14.2 Full-Life Technologies Major Business
2.14.3 Full-Life Technologies RDC Drugs Product and Solutions
2.14.4 Full-Life Technologies RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 Full-Life Technologies Recent Developments and Future Plans
2.15 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd.
2.15.1 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Details
2.15.2 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Major Business
2.15.3 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. RDC Drugs Product and Solutions
2.15.4 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.15.5 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Recent Developments and Future Plans
2.16 Nuoyu Pharmaceutical
2.16.1 Nuoyu Pharmaceutical Details
2.16.2 Nuoyu Pharmaceutical Major Business
2.16.3 Nuoyu Pharmaceutical RDC Drugs Product and Solutions
2.16.4 Nuoyu Pharmaceutical RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
2.16.5 Nuoyu Pharmaceutical Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global RDC Drugs Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of RDC Drugs by Company Revenue
3.2.2 Top 3 RDC Drugs Players Market Share in 2025
3.2.3 Top 6 RDC Drugs Players Market Share in 2025
3.3 RDC Drugs Market: Overall Company Footprint Analysis
3.3.1 RDC Drugs Market: Region Footprint
3.3.2 RDC Drugs Market: Company Product Type Footprint
3.3.3 RDC Drugs Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TARGET LIGAND TYPES
4.1 Global RDC Drugs Consumption Value and Market Share by Target Ligand Types (2021-2026)
4.2 Global RDC Drugs Market Forecast by Target Ligand Types (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global RDC Drugs Consumption Value Market Share by Application (2021-2026)
5.2 Global RDC Drugs Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America RDC Drugs Consumption Value by Target Ligand Types (2021-2032)
6.2 North America RDC Drugs Market Size by Application (2021-2032)
6.3 North America RDC Drugs Market Size by Country
6.3.1 North America RDC Drugs Consumption Value by Country (2021-2032)
6.3.2 United States RDC Drugs Market Size and Forecast (2021-2032)
6.3.3 Canada RDC Drugs Market Size and Forecast (2021-2032)
6.3.4 Mexico RDC Drugs Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe RDC Drugs Consumption Value by Target Ligand Types (2021-2032)
7.2 Europe RDC Drugs Consumption Value by Application (2021-2032)
7.3 Europe RDC Drugs Market Size by Country
7.3.1 Europe RDC Drugs Consumption Value by Country (2021-2032)
7.3.2 Germany RDC Drugs Market Size and Forecast (2021-2032)
7.3.3 France RDC Drugs Market Size and Forecast (2021-2032)
7.3.4 United Kingdom RDC Drugs Market Size and Forecast (2021-2032)
7.3.5 Russia RDC Drugs Market Size and Forecast (2021-2032)
7.3.6 Italy RDC Drugs Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific RDC Drugs Consumption Value by Target Ligand Types (2021-2032)
8.2 Asia-Pacific RDC Drugs Consumption Value by Application (2021-2032)
8.3 Asia-Pacific RDC Drugs Market Size by Region
8.3.1 Asia-Pacific RDC Drugs Consumption Value by Region (2021-2032)
8.3.2 China RDC Drugs Market Size and Forecast (2021-2032)
8.3.3 Japan RDC Drugs Market Size and Forecast (2021-2032)
8.3.4 South Korea RDC Drugs Market Size and Forecast (2021-2032)
8.3.5 India RDC Drugs Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia RDC Drugs Market Size and Forecast (2021-2032)
8.3.7 Australia RDC Drugs Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America RDC Drugs Consumption Value by Target Ligand Types (2021-2032)
9.2 South America RDC Drugs Consumption Value by Application (2021-2032)
9.3 South America RDC Drugs Market Size by Country
9.3.1 South America RDC Drugs Consumption Value by Country (2021-2032)
9.3.2 Brazil RDC Drugs Market Size and Forecast (2021-2032)
9.3.3 Argentina RDC Drugs Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa RDC Drugs Consumption Value by Target Ligand Types (2021-2032)
10.2 Middle East & Africa RDC Drugs Consumption Value by Application (2021-2032)
10.3 Middle East & Africa RDC Drugs Market Size by Country
10.3.1 Middle East & Africa RDC Drugs Consumption Value by Country (2021-2032)
10.3.2 Turkey RDC Drugs Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia RDC Drugs Market Size and Forecast (2021-2032)
10.3.4 UAE RDC Drugs Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 RDC Drugs Market Drivers
11.2 RDC Drugs Market Restraints
11.3 RDC Drugs Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 RDC Drugs Industry Chain
12.2 RDC Drugs Upstream Analysis
12.3 RDC Drugs Midstream Analysis
12.4 RDC Drugs Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global RDC Drugs Consumption Value by Target Ligand Types, (USD Million), 2021 & 2025 & 2032
Table 2. Global RDC Drugs Consumption Value by Medical Uses, (USD Million), 2021 & 2025 & 2032
Table 3. Global RDC Drugs Consumption Value by Therapeutic Radionuclide Properties, (USD Million), 2021 & 2025 & 2032
Table 4. Global RDC Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Global RDC Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 6. Global RDC Drugs Consumption Value by Region (2027-2032) & (USD Million)
Table 7. Novartis Company Information, Head Office, and Major Competitors
Table 8. Novartis Major Business
Table 9. Novartis RDC Drugs Product and Solutions
Table 10. Novartis RDC Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 11. Novartis Recent Developments and Future Plans
Table 12. Bayer Company Information, Head Office, and Major Competitors
Table 13. Bayer Major Business
Table 14. Bayer RDC Drugs Product and Solutions
Table 15. Bayer RDC Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 16. Bayer Recent Developments and Future Plans
Table 17. AstraZeneca Company Information, Head Office, and Major Competitors
Table 18. AstraZeneca Major Business
Table 19. AstraZeneca RDC Drugs Product and Solutions
Table 20. AstraZeneca RDC Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 21. Eli Lilly Company Information, Head Office, and Major Competitors
Table 22. Eli Lilly Major Business
Table 23. Eli Lilly RDC Drugs Product and Solutions
Table 24. Eli Lilly RDC Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 25. Eli Lilly Recent Developments and Future Plans
Table 26. Bristol-Myers Squibb Company Information, Head Office, and Major Competitors
Table 27. Bristol-Myers Squibb Major Business
Table 28. Bristol-Myers Squibb RDC Drugs Product and Solutions
Table 29. Bristol-Myers Squibb RDC Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 30. Bristol-Myers Squibb Recent Developments and Future Plans
Table 31. Johnson & Johnson Company Information, Head Office, and Major Competitors
Table 32. Johnson & Johnson Major Business
Table 33. Johnson & Johnson RDC Drugs Product and Solutions
Table 34. Johnson & Johnson RDC Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 35. Johnson & Johnson Recent Developments and Future Plans
Table 36. Grand Pharmaceutical Group Company Information, Head Office, and Major Competitors
Table 37. Grand Pharmaceutical Group Major Business
Table 38. Grand Pharmaceutical Group RDC Drugs Product and Solutions
Table 39. Grand Pharmaceutical Group RDC Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 40. Grand Pharmaceutical Group Recent Developments and Future Plans
Table 41. China Isotope & Radiation Corporation Company Information, Head Office, and Major Competitors
Table 42. China Isotope & Radiation Corporation Major Business
Table 43. China Isotope & Radiation Corporation RDC Drugs Product and Solutions
Table 44. China Isotope & Radiation Corporation RDC Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 45. China Isotope & Radiation Corporation Recent Developments and Future Plans
Table 46. Dongcheng Pharmaceutical Company Information, Head Office, and Major Competitors
Table 47. Dongcheng Pharmaceutical Major Business
Table 48. Dongcheng Pharmaceutical RDC Drugs Product and Solutions
Table 49. Dongcheng Pharmaceutical RDC Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 50. Dongcheng Pharmaceutical Recent Developments and Future Plans
Table 51. Hengrui Medicine Company Information, Head Office, and Major Competitors
Table 52. Hengrui Medicine Major Business
Table 53. Hengrui Medicine RDC Drugs Product and Solutions
Table 54. Hengrui Medicine RDC Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 55. Hengrui Medicine Recent Developments and Future Plans
Table 56. Xiantong Pharmaceutical Company Information, Head Office, and Major Competitors
Table 57. Xiantong Pharmaceutical Major Business
Table 58. Xiantong Pharmaceutical RDC Drugs Product and Solutions
Table 59. Xiantong Pharmaceutical RDC Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 60. Xiantong Pharmaceutical Recent Developments and Future Plans
Table 61. Bivision Company Information, Head Office, and Major Competitors
Table 62. Bivision Major Business
Table 63. Bivision RDC Drugs Product and Solutions
Table 64. Bivision RDC Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 65. Bivision Recent Developments and Future Plans
Table 66. SmartNuclide Company Information, Head Office, and Major Competitors
Table 67. SmartNuclide Major Business
Table 68. SmartNuclide RDC Drugs Product and Solutions
Table 69. SmartNuclide RDC Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 70. SmartNuclide Recent Developments and Future Plans
Table 71. Full-Life Technologies Company Information, Head Office, and Major Competitors
Table 72. Full-Life Technologies Major Business
Table 73. Full-Life Technologies RDC Drugs Product and Solutions
Table 74. Full-Life Technologies RDC Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 75. Full-Life Technologies Recent Developments and Future Plans
Table 76. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Company Information, Head Office, and Major Competitors
Table 77. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Major Business
Table 78. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. RDC Drugs Product and Solutions
Table 79. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. RDC Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 80. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Recent Developments and Future Plans
Table 81. Nuoyu Pharmaceutical Company Information, Head Office, and Major Competitors
Table 82. Nuoyu Pharmaceutical Major Business
Table 83. Nuoyu Pharmaceutical RDC Drugs Product and Solutions
Table 84. Nuoyu Pharmaceutical RDC Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Nuoyu Pharmaceutical Recent Developments and Future Plans
Table 86. Global RDC Drugs Revenue (USD Million) by Players (2021-2026)
Table 87. Global RDC Drugs Revenue Share by Players (2021-2026)
Table 88. Breakdown of RDC Drugs by Company Type (Tier 1, Tier 2, and Tier 3)
Table 89. Market Position of Players in RDC Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 90. Head Office of Key RDC Drugs Players
Table 91. RDC Drugs Market: Company Product Type Footprint
Table 92. RDC Drugs Market: Company Product Application Footprint
Table 93. RDC Drugs New Market Entrants and Barriers to Market Entry
Table 94. RDC Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 95. Global RDC Drugs Consumption Value (USD Million) by Target Ligand Types (2021-2026)
Table 96. Global RDC Drugs Consumption Value Share by Target Ligand Types (2021-2026)
Table 97. Global RDC Drugs Consumption Value Forecast by Target Ligand Types (2027-2032)
Table 98. Global RDC Drugs Consumption Value by Application (2021-2026)
Table 99. Global RDC Drugs Consumption Value Forecast by Application (2027-2032)
Table 100. North America RDC Drugs Consumption Value by Target Ligand Types (2021-2026) & (USD Million)
Table 101. North America RDC Drugs Consumption Value by Target Ligand Types (2027-2032) & (USD Million)
Table 102. North America RDC Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 103. North America RDC Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 104. North America RDC Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 105. North America RDC Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 106. Europe RDC Drugs Consumption Value by Target Ligand Types (2021-2026) & (USD Million)
Table 107. Europe RDC Drugs Consumption Value by Target Ligand Types (2027-2032) & (USD Million)
Table 108. Europe RDC Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 109. Europe RDC Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 110. Europe RDC Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 111. Europe RDC Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 112. Asia-Pacific RDC Drugs Consumption Value by Target Ligand Types (2021-2026) & (USD Million)
Table 113. Asia-Pacific RDC Drugs Consumption Value by Target Ligand Types (2027-2032) & (USD Million)
Table 114. Asia-Pacific RDC Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 115. Asia-Pacific RDC Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 116. Asia-Pacific RDC Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 117. Asia-Pacific RDC Drugs Consumption Value by Region (2027-2032) & (USD Million)
Table 118. South America RDC Drugs Consumption Value by Target Ligand Types (2021-2026) & (USD Million)
Table 119. South America RDC Drugs Consumption Value by Target Ligand Types (2027-2032) & (USD Million)
Table 120. South America RDC Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 121. South America RDC Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 122. South America RDC Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 123. South America RDC Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 124. Middle East & Africa RDC Drugs Consumption Value by Target Ligand Types (2021-2026) & (USD Million)
Table 125. Middle East & Africa RDC Drugs Consumption Value by Target Ligand Types (2027-2032) & (USD Million)
Table 126. Middle East & Africa RDC Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 127. Middle East & Africa RDC Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 128. Middle East & Africa RDC Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 129. Middle East & Africa RDC Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 130. Global Key Players of RDC Drugs Upstream (Raw Materials)
Table 131. Global RDC Drugs Typical Customers
Table 1. Global RDC Drugs Consumption Value by Target Ligand Types, (USD Million), 2021 & 2025 & 2032
Table 2. Global RDC Drugs Consumption Value by Medical Uses, (USD Million), 2021 & 2025 & 2032
Table 3. Global RDC Drugs Consumption Value by Therapeutic Radionuclide Properties, (USD Million), 2021 & 2025 & 2032
Table 4. Global RDC Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Global RDC Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 6. Global RDC Drugs Consumption Value by Region (2027-2032) & (USD Million)
Table 7. Novartis Company Information, Head Office, and Major Competitors
Table 8. Novartis Major Business
Table 9. Novartis RDC Drugs Product and Solutions
Table 10. Novartis RDC Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 11. Novartis Recent Developments and Future Plans
Table 12. Bayer Company Information, Head Office, and Major Competitors
Table 13. Bayer Major Business
Table 14. Bayer RDC Drugs Product and Solutions
Table 15. Bayer RDC Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 16. Bayer Recent Developments and Future Plans
Table 17. AstraZeneca Company Information, Head Office, and Major Competitors
Table 18. AstraZeneca Major Business
Table 19. AstraZeneca RDC Drugs Product and Solutions
Table 20. AstraZeneca RDC Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 21. Eli Lilly Company Information, Head Office, and Major Competitors
Table 22. Eli Lilly Major Business
Table 23. Eli Lilly RDC Drugs Product and Solutions
Table 24. Eli Lilly RDC Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 25. Eli Lilly Recent Developments and Future Plans
Table 26. Bristol-Myers Squibb Company Information, Head Office, and Major Competitors
Table 27. Bristol-Myers Squibb Major Business
Table 28. Bristol-Myers Squibb RDC Drugs Product and Solutions
Table 29. Bristol-Myers Squibb RDC Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 30. Bristol-Myers Squibb Recent Developments and Future Plans
Table 31. Johnson & Johnson Company Information, Head Office, and Major Competitors
Table 32. Johnson & Johnson Major Business
Table 33. Johnson & Johnson RDC Drugs Product and Solutions
Table 34. Johnson & Johnson RDC Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 35. Johnson & Johnson Recent Developments and Future Plans
Table 36. Grand Pharmaceutical Group Company Information, Head Office, and Major Competitors
Table 37. Grand Pharmaceutical Group Major Business
Table 38. Grand Pharmaceutical Group RDC Drugs Product and Solutions
Table 39. Grand Pharmaceutical Group RDC Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 40. Grand Pharmaceutical Group Recent Developments and Future Plans
Table 41. China Isotope & Radiation Corporation Company Information, Head Office, and Major Competitors
Table 42. China Isotope & Radiation Corporation Major Business
Table 43. China Isotope & Radiation Corporation RDC Drugs Product and Solutions
Table 44. China Isotope & Radiation Corporation RDC Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 45. China Isotope & Radiation Corporation Recent Developments and Future Plans
Table 46. Dongcheng Pharmaceutical Company Information, Head Office, and Major Competitors
Table 47. Dongcheng Pharmaceutical Major Business
Table 48. Dongcheng Pharmaceutical RDC Drugs Product and Solutions
Table 49. Dongcheng Pharmaceutical RDC Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 50. Dongcheng Pharmaceutical Recent Developments and Future Plans
Table 51. Hengrui Medicine Company Information, Head Office, and Major Competitors
Table 52. Hengrui Medicine Major Business
Table 53. Hengrui Medicine RDC Drugs Product and Solutions
Table 54. Hengrui Medicine RDC Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 55. Hengrui Medicine Recent Developments and Future Plans
Table 56. Xiantong Pharmaceutical Company Information, Head Office, and Major Competitors
Table 57. Xiantong Pharmaceutical Major Business
Table 58. Xiantong Pharmaceutical RDC Drugs Product and Solutions
Table 59. Xiantong Pharmaceutical RDC Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 60. Xiantong Pharmaceutical Recent Developments and Future Plans
Table 61. Bivision Company Information, Head Office, and Major Competitors
Table 62. Bivision Major Business
Table 63. Bivision RDC Drugs Product and Solutions
Table 64. Bivision RDC Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 65. Bivision Recent Developments and Future Plans
Table 66. SmartNuclide Company Information, Head Office, and Major Competitors
Table 67. SmartNuclide Major Business
Table 68. SmartNuclide RDC Drugs Product and Solutions
Table 69. SmartNuclide RDC Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 70. SmartNuclide Recent Developments and Future Plans
Table 71. Full-Life Technologies Company Information, Head Office, and Major Competitors
Table 72. Full-Life Technologies Major Business
Table 73. Full-Life Technologies RDC Drugs Product and Solutions
Table 74. Full-Life Technologies RDC Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 75. Full-Life Technologies Recent Developments and Future Plans
Table 76. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Company Information, Head Office, and Major Competitors
Table 77. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Major Business
Table 78. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. RDC Drugs Product and Solutions
Table 79. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. RDC Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 80. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Recent Developments and Future Plans
Table 81. Nuoyu Pharmaceutical Company Information, Head Office, and Major Competitors
Table 82. Nuoyu Pharmaceutical Major Business
Table 83. Nuoyu Pharmaceutical RDC Drugs Product and Solutions
Table 84. Nuoyu Pharmaceutical RDC Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Nuoyu Pharmaceutical Recent Developments and Future Plans
Table 86. Global RDC Drugs Revenue (USD Million) by Players (2021-2026)
Table 87. Global RDC Drugs Revenue Share by Players (2021-2026)
Table 88. Breakdown of RDC Drugs by Company Type (Tier 1, Tier 2, and Tier 3)
Table 89. Market Position of Players in RDC Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 90. Head Office of Key RDC Drugs Players
Table 91. RDC Drugs Market: Company Product Type Footprint
Table 92. RDC Drugs Market: Company Product Application Footprint
Table 93. RDC Drugs New Market Entrants and Barriers to Market Entry
Table 94. RDC Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 95. Global RDC Drugs Consumption Value (USD Million) by Target Ligand Types (2021-2026)
Table 96. Global RDC Drugs Consumption Value Share by Target Ligand Types (2021-2026)
Table 97. Global RDC Drugs Consumption Value Forecast by Target Ligand Types (2027-2032)
Table 98. Global RDC Drugs Consumption Value by Application (2021-2026)
Table 99. Global RDC Drugs Consumption Value Forecast by Application (2027-2032)
Table 100. North America RDC Drugs Consumption Value by Target Ligand Types (2021-2026) & (USD Million)
Table 101. North America RDC Drugs Consumption Value by Target Ligand Types (2027-2032) & (USD Million)
Table 102. North America RDC Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 103. North America RDC Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 104. North America RDC Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 105. North America RDC Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 106. Europe RDC Drugs Consumption Value by Target Ligand Types (2021-2026) & (USD Million)
Table 107. Europe RDC Drugs Consumption Value by Target Ligand Types (2027-2032) & (USD Million)
Table 108. Europe RDC Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 109. Europe RDC Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 110. Europe RDC Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 111. Europe RDC Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 112. Asia-Pacific RDC Drugs Consumption Value by Target Ligand Types (2021-2026) & (USD Million)
Table 113. Asia-Pacific RDC Drugs Consumption Value by Target Ligand Types (2027-2032) & (USD Million)
Table 114. Asia-Pacific RDC Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 115. Asia-Pacific RDC Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 116. Asia-Pacific RDC Drugs Consumption Value by Region (2021-2026) & (USD Million)
Table 117. Asia-Pacific RDC Drugs Consumption Value by Region (2027-2032) & (USD Million)
Table 118. South America RDC Drugs Consumption Value by Target Ligand Types (2021-2026) & (USD Million)
Table 119. South America RDC Drugs Consumption Value by Target Ligand Types (2027-2032) & (USD Million)
Table 120. South America RDC Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 121. South America RDC Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 122. South America RDC Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 123. South America RDC Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 124. Middle East & Africa RDC Drugs Consumption Value by Target Ligand Types (2021-2026) & (USD Million)
Table 125. Middle East & Africa RDC Drugs Consumption Value by Target Ligand Types (2027-2032) & (USD Million)
Table 126. Middle East & Africa RDC Drugs Consumption Value by Application (2021-2026) & (USD Million)
Table 127. Middle East & Africa RDC Drugs Consumption Value by Application (2027-2032) & (USD Million)
Table 128. Middle East & Africa RDC Drugs Consumption Value by Country (2021-2026) & (USD Million)
Table 129. Middle East & Africa RDC Drugs Consumption Value by Country (2027-2032) & (USD Million)
Table 130. Global Key Players of RDC Drugs Upstream (Raw Materials)
Table 131. Global RDC Drugs Typical Customers
LIST OF FIGURES
Figure 1. RDC Drugs Picture
Figure 2. Global RDC Drugs Consumption Value by Target Ligand Types, (USD Million), 2021 & 2025 & 2032
Figure 3. Global RDC Drugs Consumption Value Market Share by Target Ligand Types in 2025
Figure 4. Antibody-Drug Conjugates (ARC)
Figure 5. Peptide-Drug Conjugates (PRC)
Figure 6. Small Molecule-Drug Conjugates (SMRC)
Figure 7. Global RDC Drugs Consumption Value by Medical Uses, (USD Million), 2021 & 2025 & 2032
Figure 8. Global RDC Drugs Consumption Value Market Share by Medical Uses in 2025
Figure 9. Diagnostic RDCs
Figure 10. Therapeutic RDCs
Figure 11. Global RDC Drugs Consumption Value by Therapeutic Radionuclide Properties, (USD Million), 2021 & 2025 & 2032
Figure 12. Global RDC Drugs Consumption Value Market Share by Therapeutic Radionuclide Properties in 2025
Figure 13. ?-Nuclear Therapy
Figure 14. ?-Nuclear Therapy
Figure 15. Global RDC Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 16. RDC Drugs Consumption Value Market Share by Application in 2025
Figure 17. Prostate Cancer Picture
Figure 18. Neuroendocrine Tumors Picture
Figure 19. Liver Cancer Picture
Figure 20. Kidney Cancer Picture
Figure 21. Bone Metastases Picture
Figure 22. Others Picture
Figure 23. Global RDC Drugs Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 24. Global RDC Drugs Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 25. Global Market RDC Drugs Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 26. Global RDC Drugs Consumption Value Market Share by Region (2021-2032)
Figure 27. Global RDC Drugs Consumption Value Market Share by Region in 2025
Figure 28. North America RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 29. Europe RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 30. Asia-Pacific RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 31. South America RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 32. Middle East & Africa RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 33. Company Three Recent Developments and Future Plans
Figure 34. Global RDC Drugs Revenue Share by Players in 2025
Figure 35. RDC Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 36. Market Share of RDC Drugs by Player Revenue in 2025
Figure 37. Top 3 RDC Drugs Players Market Share in 2025
Figure 38. Top 6 RDC Drugs Players Market Share in 2025
Figure 39. Global RDC Drugs Consumption Value Share by Target Ligand Types (2021-2026)
Figure 40. Global RDC Drugs Market Share Forecast by Target Ligand Types (2027-2032)
Figure 41. Global RDC Drugs Consumption Value Share by Application (2021-2026)
Figure 42. Global RDC Drugs Market Share Forecast by Application (2027-2032)
Figure 43. North America RDC Drugs Consumption Value Market Share by Target Ligand Types (2021-2032)
Figure 44. North America RDC Drugs Consumption Value Market Share by Application (2021-2032)
Figure 45. North America RDC Drugs Consumption Value Market Share by Country (2021-2032)
Figure 46. United States RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 47. Canada RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 48. Mexico RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 49. Europe RDC Drugs Consumption Value Market Share by Target Ligand Types (2021-2032)
Figure 50. Europe RDC Drugs Consumption Value Market Share by Application (2021-2032)
Figure 51. Europe RDC Drugs Consumption Value Market Share by Country (2021-2032)
Figure 52. Germany RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 53. France RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 54. United Kingdom RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 55. Russia RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 56. Italy RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 57. Asia-Pacific RDC Drugs Consumption Value Market Share by Target Ligand Types (2021-2032)
Figure 58. Asia-Pacific RDC Drugs Consumption Value Market Share by Application (2021-2032)
Figure 59. Asia-Pacific RDC Drugs Consumption Value Market Share by Region (2021-2032)
Figure 60. China RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 61. Japan RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 62. South Korea RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 63. India RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 64. Southeast Asia RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 65. Australia RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 66. South America RDC Drugs Consumption Value Market Share by Target Ligand Types (2021-2032)
Figure 67. South America RDC Drugs Consumption Value Market Share by Application (2021-2032)
Figure 68. South America RDC Drugs Consumption Value Market Share by Country (2021-2032)
Figure 69. Brazil RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 70. Argentina RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 71. Middle East & Africa RDC Drugs Consumption Value Market Share by Target Ligand Types (2021-2032)
Figure 72. Middle East & Africa RDC Drugs Consumption Value Market Share by Application (2021-2032)
Figure 73. Middle East & Africa RDC Drugs Consumption Value Market Share by Country (2021-2032)
Figure 74. Turkey RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 75. Saudi Arabia RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 76. UAE RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 77. RDC Drugs Market Drivers
Figure 78. RDC Drugs Market Restraints
Figure 79. RDC Drugs Market Trends
Figure 80. Porters Five Forces Analysis
Figure 81. RDC Drugs Industrial Chain
Figure 82. Methodology
Figure 83. Research Process and Data Source
Figure 1. RDC Drugs Picture
Figure 2. Global RDC Drugs Consumption Value by Target Ligand Types, (USD Million), 2021 & 2025 & 2032
Figure 3. Global RDC Drugs Consumption Value Market Share by Target Ligand Types in 2025
Figure 4. Antibody-Drug Conjugates (ARC)
Figure 5. Peptide-Drug Conjugates (PRC)
Figure 6. Small Molecule-Drug Conjugates (SMRC)
Figure 7. Global RDC Drugs Consumption Value by Medical Uses, (USD Million), 2021 & 2025 & 2032
Figure 8. Global RDC Drugs Consumption Value Market Share by Medical Uses in 2025
Figure 9. Diagnostic RDCs
Figure 10. Therapeutic RDCs
Figure 11. Global RDC Drugs Consumption Value by Therapeutic Radionuclide Properties, (USD Million), 2021 & 2025 & 2032
Figure 12. Global RDC Drugs Consumption Value Market Share by Therapeutic Radionuclide Properties in 2025
Figure 13. ?-Nuclear Therapy
Figure 14. ?-Nuclear Therapy
Figure 15. Global RDC Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 16. RDC Drugs Consumption Value Market Share by Application in 2025
Figure 17. Prostate Cancer Picture
Figure 18. Neuroendocrine Tumors Picture
Figure 19. Liver Cancer Picture
Figure 20. Kidney Cancer Picture
Figure 21. Bone Metastases Picture
Figure 22. Others Picture
Figure 23. Global RDC Drugs Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 24. Global RDC Drugs Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 25. Global Market RDC Drugs Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 26. Global RDC Drugs Consumption Value Market Share by Region (2021-2032)
Figure 27. Global RDC Drugs Consumption Value Market Share by Region in 2025
Figure 28. North America RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 29. Europe RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 30. Asia-Pacific RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 31. South America RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 32. Middle East & Africa RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 33. Company Three Recent Developments and Future Plans
Figure 34. Global RDC Drugs Revenue Share by Players in 2025
Figure 35. RDC Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 36. Market Share of RDC Drugs by Player Revenue in 2025
Figure 37. Top 3 RDC Drugs Players Market Share in 2025
Figure 38. Top 6 RDC Drugs Players Market Share in 2025
Figure 39. Global RDC Drugs Consumption Value Share by Target Ligand Types (2021-2026)
Figure 40. Global RDC Drugs Market Share Forecast by Target Ligand Types (2027-2032)
Figure 41. Global RDC Drugs Consumption Value Share by Application (2021-2026)
Figure 42. Global RDC Drugs Market Share Forecast by Application (2027-2032)
Figure 43. North America RDC Drugs Consumption Value Market Share by Target Ligand Types (2021-2032)
Figure 44. North America RDC Drugs Consumption Value Market Share by Application (2021-2032)
Figure 45. North America RDC Drugs Consumption Value Market Share by Country (2021-2032)
Figure 46. United States RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 47. Canada RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 48. Mexico RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 49. Europe RDC Drugs Consumption Value Market Share by Target Ligand Types (2021-2032)
Figure 50. Europe RDC Drugs Consumption Value Market Share by Application (2021-2032)
Figure 51. Europe RDC Drugs Consumption Value Market Share by Country (2021-2032)
Figure 52. Germany RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 53. France RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 54. United Kingdom RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 55. Russia RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 56. Italy RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 57. Asia-Pacific RDC Drugs Consumption Value Market Share by Target Ligand Types (2021-2032)
Figure 58. Asia-Pacific RDC Drugs Consumption Value Market Share by Application (2021-2032)
Figure 59. Asia-Pacific RDC Drugs Consumption Value Market Share by Region (2021-2032)
Figure 60. China RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 61. Japan RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 62. South Korea RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 63. India RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 64. Southeast Asia RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 65. Australia RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 66. South America RDC Drugs Consumption Value Market Share by Target Ligand Types (2021-2032)
Figure 67. South America RDC Drugs Consumption Value Market Share by Application (2021-2032)
Figure 68. South America RDC Drugs Consumption Value Market Share by Country (2021-2032)
Figure 69. Brazil RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 70. Argentina RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 71. Middle East & Africa RDC Drugs Consumption Value Market Share by Target Ligand Types (2021-2032)
Figure 72. Middle East & Africa RDC Drugs Consumption Value Market Share by Application (2021-2032)
Figure 73. Middle East & Africa RDC Drugs Consumption Value Market Share by Country (2021-2032)
Figure 74. Turkey RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 75. Saudi Arabia RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 76. UAE RDC Drugs Consumption Value (2021-2032) & (USD Million)
Figure 77. RDC Drugs Market Drivers
Figure 78. RDC Drugs Market Restraints
Figure 79. RDC Drugs Market Trends
Figure 80. Porters Five Forces Analysis
Figure 81. RDC Drugs Industrial Chain
Figure 82. Methodology
Figure 83. Research Process and Data Source
